.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Federal Trade Commission
Healthtrust
Harvard Business School
Dow
Fuji
Julphar
UBS
Cerilliant
Deloitte

Generated: September 23, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 065326

« Back to Dashboard
NDA 065326 describes CEPHALEXIN, which is a drug marketed by Teva, Sun Pharm Inds Ltd, Purepac Pharm, Belcher Pharms, Hikma, Facta Farma, Orchid Hlthcare, Barr, Lupin, Alkem Labs Ltd, Yung Shin Pharm, Hikma Pharms, Aurobindo Pharma Ltd, Apothecon, Vitarine, Ivax Sub Teva Pharms, Stevens J, Yoshitomi, and Sun Pharm Inds (in), and is included in forty-nine NDAs. It is available from sixty-two suppliers. Additional details are available on the CEPHALEXIN profile page.

The generic ingredient in CEPHALEXIN is cephalexin. There are twenty-nine drug master file entries for this compound. Sixty-five suppliers are listed for this compound. Additional details are available on the cephalexin profile page.

Summary for NDA: 065326

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details

Pharmacology for NDA: 065326

Ingredient-typeCephalosporins

Suppliers and Packaging for NDA: 065326

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CEPHALEXIN
cephalexin
FOR SUSPENSION;ORAL 065326 ANDA STAT RX USA LLC 16590-049 16590-049-36 200 mL in 1 BOTTLE (16590-049-36)
CEPHALEXIN
cephalexin
FOR SUSPENSION;ORAL 065326 ANDA STAT RX USA LLC 16590-466 16590-466-32 100 mL in 1 BOTTLE (16590-466-32)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:FOR SUSPENSION;ORALStrengthEQ 125MG BASE/5ML
Approval Date:Jul 10, 2006TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:FOR SUSPENSION;ORALStrengthEQ 250MG BASE/5ML
Approval Date:Jul 10, 2006TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Chinese Patent Office
Healthtrust
Teva
Accenture
Mallinckrodt
Express Scripts
Johnson and Johnson
AstraZeneca
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot